APHD-012 is under clinical development by Aphaia Pharma and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 28% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how APHD-012’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
APHD-012 is under development for the treatment of obesity. The therapeutic candidate comprises distal jejunal-release dextrose beads (Aphaia technology, AT).
For a complete picture of APHD-012’s drug-specific PTSR and LoA scores, buy the report here.